The alkylating agent temozolomide has also shown promise in treating metastatic neuroendocrine tumors, with one study reporting a 70% reduction in tumor size in a SDHB-mutation-positive patient (18). This evidence concerns the gene SDHB and neuroendocrine neoplasm.